Rigel Pharmaceuticals (RIGL) Assets (2010 - 2026)
Rigel Pharmaceuticals' quarterly Assets came in at $504.6 million in Q1 2026, up 186.75% year-on-year from $176.0 million in Q1 2025, and down 1.75% quarter-over-quarter from $513.6 million in Q4 2025.
Rigel Pharmaceuticals has reported Assets for 17 years, with the latest figure at $504.6 million in Q1 2026.
- For the quarter ending Q1 2026, Assets rose 186.75% year-over-year to $504.6 million; the trailing twelve-month figure through Mar 2026 stood at $504.6 million (up 186.75% YoY), and the FY2025 full-year result was $513.6 million, up 213.21% from the prior year.
- Assets for Q1 2026 stood at $504.6 million, down from $513.6 million in the prior quarter.
- The five-year high for Assets was $513.6 million in Q4 2025, with the low at $115.3 million in Q3 2023.
- Average Assets over 5 years is $188.4 million, with a median of $134.3 million recorded in 2022.
- Year-over-year, Assets sank 38.02% in 2022 and surged 213.21% in 2025.
- Tracing RIGL's Assets over 5 years: stood at $134.3 million in 2022, then slipped by 12.7% to $117.2 million in 2023, then jumped by 39.88% to $164.0 million in 2024, then surged by 213.21% to $513.6 million in 2025, then slipped by 1.75% to $504.6 million in 2026.
- The last three Assets figures came in at $504.6 million (Q1 2026), $513.6 million (Q4 2025), and $242.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 504.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 504.61 Mn |
| Dec 31, 2025 | 513.59 Mn |
| Sep 30, 2025 | 242.53 Mn |
| Jun 30, 2025 | 206.74 Mn |
| Mar 31, 2025 | 175.97 Mn |
| Dec 31, 2024 | 163.98 Mn |
| Sep 30, 2024 | 139.42 Mn |
| Jun 30, 2024 | 128.41 Mn |
| Mar 31, 2024 | 126.52 Mn |
| Dec 31, 2023 | 117.23 Mn |
| Sep 30, 2023 | 115.32 Mn |
| Jun 30, 2023 | 117.09 Mn |
| Mar 31, 2023 | 123.61 Mn |
| Dec 31, 2022 | 134.28 Mn |
| Sep 30, 2022 | 115.61 Mn |
| Jun 30, 2022 | 128.00 Mn |
| Mar 31, 2022 | 149.07 Mn |
| Dec 31, 2021 | 167.33 Mn |
| Sep 30, 2021 | 186.52 Mn |
| Jun 30, 2021 | 201.60 Mn |
| Mar 31, 2021 | 215.99 Mn |
| Dec 31, 2020 | 110.38 Mn |
| Sep 30, 2020 | 123.06 Mn |
| Jun 30, 2020 | 138.04 Mn |
| Mar 31, 2020 | 143.36 Mn |
| Dec 31, 2019 | 147.57 Mn |
| Sep 30, 2019 | 156.06 Mn |
| Jun 30, 2019 | 156.16 Mn |
| Mar 31, 2019 | 172.78 Mn |
| Dec 31, 2018 | 139.11 Mn |
| Sep 30, 2018 | 123.17 Mn |
| Jun 30, 2018 | 141.22 Mn |
| Mar 31, 2018 | 98.81 Mn |
| Dec 31, 2017 | 119.11 Mn |
| Sep 30, 2017 | 71.25 Mn |
| Jun 30, 2017 | 85.48 Mn |
| Mar 31, 2017 | 101.33 Mn |
| Dec 31, 2016 | 78.13 Mn |
| Sep 30, 2016 | 88.64 Mn |
| Jun 30, 2016 | 99.32 Mn |
| Mar 31, 2016 | 108.28 Mn |
| Dec 31, 2015 | 131.75 Mn |
| Sep 30, 2015 | 139.17 Mn |
| Jun 30, 2015 | 148.35 Mn |
| Mar 31, 2015 | 165.69 Mn |
| Dec 31, 2014 | 154.14 Mn |
| Sep 30, 2014 | 163.22 Mn |
| Jun 30, 2014 | 182.43 Mn |
| Mar 31, 2014 | 203.29 Mn |
| Dec 31, 2013 | 226.06 Mn |
| Sep 30, 2013 | 239.54 Mn |
| Jun 30, 2013 | 261.67 Mn |
| Mar 31, 2013 | 282.94 Mn |
| Dec 31, 2012 | 310.04 Mn |
| Sep 30, 2012 | 194.32 Mn |
| Jun 30, 2012 | 214.36 Mn |
| Mar 31, 2012 | 233.91 Mn |
| Dec 31, 2011 | 257.11 Mn |
| Sep 30, 2011 | 275.87 Mn |
| Jun 30, 2011 | 289.87 Mn |
| Dec 31, 2010 | 186.70 Mn |